Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Innovation Launches JLINX To Catalyze Company Formation

This article was originally published in Scrip

Executive Summary

Johnson & Johnson Innovation is expanding its innovation strategy to include a new initiative in Europe that combines venture investment and company incubation. The initiative is called JLINX and it is hoped that it will catalyze scientific innovation and successful company formation by offering start-ups flexible ways to grow and collaborate across the European life science ecosystem.

You may also be interested in...



Tech Transfer Roundup: J&J Innovation’s Agnostic Approach To Academic Collaboration

J&J’s Robert Urban explains how his organization’s efforts lead to partnerships with academia across a broad range of areas, including pharmaceuticals, medical devices and consumer products. Also, transactions occurring between Nov. 21 and Dec. 21, including the expansion and solidification of Editas Medicine’s IP estate in CRISPR technology.

Finding Cutting-Edge Science Takes A Broad Net, J&J Innovation’s Urban Says

Reflecting on the latest batch of deals, Global Head Robert Urban discusses the progress J&J Innovation has made so far and the next steps as it launches its JLINX incubator.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel